Covid-19 roundup: Regeneron puts its antibodies into the clinic, racing with Eli Lilly for fall authorization
Regeneron, arguably the most-watched developer of a Covid-19 antibody treatment, is beginning clinical trials.
Like other antibody developers, the big Tarrytown, NY biotech will be testing the drug both as a way of treating Covid-19 patients and preventing people at high-risk from contracting the virus. They’ll conduct four different trials, beginning today with a trial for hospitalized patients and a trial for non-hospitalized. Two preventative trials will come later.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.